Developing a Childhood Asthma Risk Passive Digital Marker

N/A Terminated NCT05826561

Summary

Underdiagnosis and undertreatment is a major problem in childhood asthma management, especially in preschool-aged children. Current prognostic approaches using risk-score based tools have poor-to-modest accuracy, are impractical, and have limited evidence of efficacy in clinical settings and hence are not widely used in practice. The objective of the study is to determine the usability, acceptability, feasibility, and preliminary efficacy of the childhood asthma passive digital marker (PDM) among pediatricians. The study will include practicing pediatricians within the IU Health Network.

Perceived PDM Acceptance

8 to 12 months · Score on a Likert Scale (0-5)

Perceived PDM Usability

8 to 12 months · Score on a Likert Scale (0-5)

Study Feasibility

8 to 12 months · Participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
• A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
• A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
• A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
• Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca
• Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma — ARS Pharmaceuticals, Inc.

All trials